Endocrinology

This episode covers the upcoming release of Dexcom's G7 15-day patch and major price cuts for semaglutide.

Eli Lilly and Company’s investigative therapy provided effective and safe weight loss treatment with limited adverse events.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Based on results from the THRIVE and THRIVE-2 phase 3 studies, this Biologics License Application includes a request for Priority Review.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.

This episode covers the recent approval of oral semaglutide for T2D and a pre-specified subanalysis of the SELECT trial.

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

A post hoc analysis of the PLIS study has highlighted the comparative effectiveness of glucose levels in achieving prediabetes remission.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

Stay updated with the latest healthcare breakthroughs, including FDA updates and phase 3 trial readouts, in this week's essential news roundup.

New research links sleep-related leg movements to a higher risk of diabetes.

This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

A recent study indicates the potential benefits of consistent follow-up in diabetes through tele-education, teleconsultation, and digital data support.

Investigators urge clinicians to support teenage patients with type 1 diabetes in managing their blood sugar and transitioning to adult care.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.

Lifelong reliance on insulin, constant glucose monitoring, and management of hypo- and hyperglycemia require substantial lifestyle changes.

Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.